We are happy to present you our newest application note.

In this application note we will discuss the new research possibilities offered by Nanolive’s newest microscope, the CX-A, for the study of drug-induced perturbations. In detail, you can:

Learn how Nanolive’s CX-A allows for the acquisition of very powerful 3D images and 4D time-lapses of living cells in a multi-well plate format.
Learn how to perform multiple label-free drug perturbation assays, live and over long periods of time.

Following video demonstrates a time-lapse of a comparative study of multiple drug perturbations performed in a multi-well setup featuring pre-adipocytes perturbed by various drugs. We applied the following treatments on pre-adipocyte cells: Tamoxifen, Raptinal and Shikonin at various concentrations, with or without mitoTracker and observed the effects of such drugs over
26 hours compared to the relevant control conditions.

Please download the full application note from here:

Download

Read our latest news

Unlocking mitochondrial stress as a drug discovery readout

Feb 25, 2026 | News

Mitochondrial stress can act as an early warning biomarker for drug candidate toxicity and can appear hours before conventional cell viability results. Discover case study data demonstrating how mitochondrial stress can be used as an early warning biomarker for cytotoxicity prediction.

Trends in AI analysis for live cell imaging

Jan 19, 2026 | News

We review recent peer-reviewed studies that relied on noninvasive live-cell imaging to study immuno-oncology, cellular metabolism and disease progression in 2025, and share how advances in image analysis are supporting consistent interpretation of complex live-cell data in preclinical research.

2025’s Breakthroughs in AI-Driven Live Cell Analytics

Dec 19, 2025 | News

We look back at some of 2025’s major advances in AI-driven live cell analytics, from automated mitochondrial segmentation to dynamic EC50 profiling and next-generation T-cell insights. These breakthroughs bring deeper, label-free understanding to drug discovery and immuno-oncology.

More news